Compare CNS & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNS | PTCT |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 5.3B |
| IPO Year | 2004 | 2013 |
| Metric | CNS | PTCT |
|---|---|---|
| Price | $62.29 | $77.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $72.50 | ★ $73.76 |
| AVG Volume (30 Days) | 535.9K | ★ 2.3M |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | ★ 18.87 | N/A |
| EPS | 3.19 | ★ 8.94 |
| Revenue | $552,096,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $8.26 | $128.32 |
| Revenue Next Year | $10.55 | N/A |
| P/E Ratio | $19.51 | ★ $8.64 |
| Revenue Growth | 11.13 | ★ 97.54 |
| 52 Week Low | $58.80 | $35.95 |
| 52 Week High | $102.57 | $87.50 |
| Indicator | CNS | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 54.29 |
| Support Level | $61.59 | $73.03 |
| Resistance Level | $64.43 | $79.03 |
| Average True Range (ATR) | 1.82 | 3.38 |
| MACD | 0.21 | -0.70 |
| Stochastic Oscillator | 57.52 | 29.37 |
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.